Appendix:

Table 5: Systemic treatments given before and after pazopanib

|  | **Patients received previous line treatment agents(N=46)** | **Patients received further line treatment agents****(N=38)** |
| --- | --- | --- |
|  | **Yes****N (%)** | **Yes****N (%)** |
| **Paclitaxel**  |  25 (54.3)  | 7 (18.4) |
| **Doxorubicin** |  20 (43.5)  | 2 (5.3) |
| **Docetaxel**  |  11 (23.9)  | 2 (5.3) |
| **Gemcitabine**  |  11 (23.9)  | 8 (21.1) |
| **Ifosfamide**  |  8 (17.4)  | 1 (2.6) |
| **Epirubicin**  |  7 (15.2)  | 0 |
| **Dacarbazine** |  3 (6.5)  | 1 (2.6) |
| **Brentuximab** |  2 (4.3)  | 0 |
| **Trabectedin** |  2 (4.3)  | 1 (2.6) |
| **Alpha interferon** |  1 (2.2)  | 0 |
| **Carboplatin**  |  1 (2.2)  | 0 |
| **Cyclophosphamide** |  1 (2.2)  | 2 (5.3) |
| **Lenalidomide**  |  1 (2.2)  | 0 |
| **Melphalan** |  1 (2.2)  | 0 |
| **Vinorelbine** |  1 (2.2)  | 0 |
| **Thalidomide** |  1 (2.2)  | 0 |
| **Cisplatin** | 0 | 1 (2.6) |
| **Etoposide** | 0 | 1 (2.6) |
| **Pembrolizumab** | 0 | 1 (2.6) |
| **Trofosfamide** | 0 | 1 (2.6) |